The interaction between prognostic and pharmacodynamic biomarkers

L. Bouranis, M. Sperrin, A. Greystoke, C. Dive, A. G. Renehan

Research output: Contribution to journalArticlepeer-review


Background:Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention.Methods:Prognostic and PD utilities were assessed with linear mixed-effects models using published data on repeated measurements of circulating caspase-cleaved (ctCK18) and total (tCK18) cytokeratin 18, in 57 patients with metastatic colorectal cancer undergoing chemotherapy.Results:The model for tCK18 (but not cCK18) separated the prognostic/PD interaction from the pure prognostic effect, illustrating the principle of dual prognostic and PD characteristics for a given biomarker.Conclusion:These models provide the framework for the analysis and interpretation of longitudinal data to detect prognostic/PD biomarker interactions. © 2013 Cancer Research UK.
Original languageEnglish
Pages (from-to)1782-1785
Number of pages3
JournalBritish Journal of Cancer
Issue number7
Publication statusPublished - 1 Oct 2013


  • biomarkers
  • colorectal cancer
  • pharmacodynamics
  • prognosis


Dive into the research topics of 'The interaction between prognostic and pharmacodynamic biomarkers'. Together they form a unique fingerprint.

Cite this